CassandraBio
Pipeline dossier

NIH & clinical-trial pipeline signals for REGENERON PHARMACEUTICALS, INC. (REGN)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for REGN, mapped to public ticker REGN (CIK 0000872589). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →
Trial → FilingREGN55% conf

REGENERON PHARMACEUTICALS, INC. (REGN) — PHASE2 primary completion in ~145 days

Upstream (observed)
Clinical trial status (PHASE2) — Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)
trial ↗filings ↗

Recent SEC 8-K filings

JSON API for this entity →